Cargando…

Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder

Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Shannon, Niyazov, Dmitriy M., Rossignol, Daniel A., Goldenthal, Michael, Kahler, Stephen G., Frye, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132446/
https://www.ncbi.nlm.nih.gov/pubmed/30039193
http://dx.doi.org/10.1007/s40291-018-0352-x
_version_ 1783354324006469632
author Rose, Shannon
Niyazov, Dmitriy M.
Rossignol, Daniel A.
Goldenthal, Michael
Kahler, Stephen G.
Frye, Richard E.
author_facet Rose, Shannon
Niyazov, Dmitriy M.
Rossignol, Daniel A.
Goldenthal, Michael
Kahler, Stephen G.
Frye, Richard E.
author_sort Rose, Shannon
collection PubMed
description Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and the brains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD.
format Online
Article
Text
id pubmed-6132446
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-61324462018-09-14 Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder Rose, Shannon Niyazov, Dmitriy M. Rossignol, Daniel A. Goldenthal, Michael Kahler, Stephen G. Frye, Richard E. Mol Diagn Ther Review Article Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and the brains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD. Springer International Publishing 2018-07-23 2018 /pmc/articles/PMC6132446/ /pubmed/30039193 http://dx.doi.org/10.1007/s40291-018-0352-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Rose, Shannon
Niyazov, Dmitriy M.
Rossignol, Daniel A.
Goldenthal, Michael
Kahler, Stephen G.
Frye, Richard E.
Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title_full Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title_fullStr Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title_full_unstemmed Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title_short Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
title_sort clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132446/
https://www.ncbi.nlm.nih.gov/pubmed/30039193
http://dx.doi.org/10.1007/s40291-018-0352-x
work_keys_str_mv AT roseshannon clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder
AT niyazovdmitriym clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder
AT rossignoldaniela clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder
AT goldenthalmichael clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder
AT kahlerstepheng clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder
AT fryericharde clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder